{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:17:59Z","timestamp":1771928279533,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Management of chronic inflammatory demyelinating polyneuropathy (CIDP) is challenged by heterogeneity in severity, comorbidities, potential adverse effects, and treatment accessibility. This study aimed to elucidate treatment utilization among patients with CIDP in the United States (US) to identify potential unmet needs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients with CIDP were identified using Komodo Health\u2019s Healthcare Map\u2122 (January 2016\u2013December 2020). Descriptive statistics related to utilization of CIDP treatments over 1-year post-index were analyzed. Among patients who used immunoglobulin (Ig), chronic Ig users were defined as patients with \u22658 Ig courses, and intermittent Ig users as patients with &amp;lt;8 Ig courses during 1-year post-index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 3,409 patients with CIDP identified, the majority (81% [\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f2,758]) were treated for CIDP while 19% (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f651) were untreated for CIDP during 1-year post-index. Steroids (73% [\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f2017]) followed by Ig (65% [\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f1,803]) were most commonly utilized. Of patients who used Ig, 62% (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f1,113) were chronic and 38% (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f690) were intermittent users during the 1-year post-index. A large proportion of Ig users received concomitant CIDP treatments, most commonly steroids. Patients who received &amp;gt;60\u202fmg\/day oral steroids on average over the 1-year post-index continued to use concomitant CIDP treatment, most commonly Ig.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Steroids and Ig were mainstay treatments among patients with CIDP. A substantial proportion of Ig users were chronic users who also received other CIDP therapies, with steroids being most common. This suggests a potentially pronounced burden among patients treated with frequent Ig and steroids.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1726857","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:21:15Z","timestamp":1769700075000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment utilization in adults with chronic inflammatory demyelinating polyneuropathy in the United States"],"prefix":"10.3389","volume":"16","author":[{"given":"C\u00e9cile","family":"Blein","sequence":"first","affiliation":[{"name":"argenx BVBA","place":["Ghent, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chafic","family":"Karam","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mence","family":"Arvin-Berod","sequence":"additional","affiliation":[{"name":"argenx BVBA","place":["Ghent, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Gelinas","sequence":"additional","affiliation":[{"name":"argenx US, Inc.","place":["Boston, MA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Barrera-Sierra","sequence":"additional","affiliation":[{"name":"argenx BVBA","place":["Ghent, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hashmath Ulla T. A.","family":"Syed","sequence":"additional","affiliation":[{"name":"ZS Associates","place":["Bengaluru, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Ward","sequence":"additional","affiliation":[{"name":"ZS Associates","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Goyal","sequence":"additional","affiliation":[{"name":"ZS Associates","place":["Princeton, NJ, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Guptill","sequence":"additional","affiliation":[{"name":"argenx US, Inc.","place":["Boston, MA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jns.12455","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision","volume":"26","author":"den Van Bergh","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1212\/WNL.0b013e3181aaea47","article-title":"Incidence and prevalence of CIDP and the association of diabetes mellitus","volume":"73","author":"Laughlin","year":"2009","journal-title":"Neurology"},{"key":"ref3","volume-title":"Chronic inflammatory demyelinating Polyradiculoneuropathy: StatPearls","author":"Gogia","year":"2024"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1007\/s00415-020-10287-7","article-title":"Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy","volume":"268","author":"Chaudhary","year":"2021","journal-title":"J Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1212\/WNL.0000000000001833","article-title":"CIDP diagnostic pitfalls and perception of treatment benefit","volume":"85","author":"Allen","year":"2015","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/TCRM.S360249","article-title":"Challenges in the early diagnosis and treatment of chronic inflammatory demyelinating Polyradiculoneuropathy in adults: current perspectives","volume":"20","author":"van Doorn","year":"2024","journal-title":"Ther Clin Risk Manag"},{"key":"ref7","first-page":"S371","article-title":"Chronic inflammatory demyelinating polyneuropathy: considerations for diagnosis, management, and population health","volume":"24","author":"Ryan","year":"2018","journal-title":"Am J Manag Care"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1177\/1756285612457215","article-title":"An update on the management of chronic inflammatory demyelinating polyneuropathy","volume":"5","author":"Gorson","year":"2012","journal-title":"Ther Adv Neurol Disord"},{"key":"ref9","first-page":"127","article-title":"Treatment patterns and costs of chronic inflammatory demyelinating polyneuropathy: a claims database analysis","volume":"12","author":"Guptill","year":"2019","journal-title":"Am Health Drug Benefits"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/mus.25271","article-title":"Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy","volume":"55","author":"Kaplan","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"5930","DOI":"10.1007\/s00415-024-12548-1","article-title":"Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort","volume":"271","author":"Quint","year":"2024","journal-title":"J Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"117098","DOI":"10.1016\/j.jns.2020.117098","article-title":"Refractory CIDP: clinical characteristics, antibodies and response to alternative treatment","volume":"418","author":"Godil","year":"2020","journal-title":"J Neurol Sci"},{"key":"ref13","year":"2024"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1080\/08916934.2022.2104261","article-title":"Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis","volume":"55","author":"Guptill","year":"2022","journal-title":"Autoimmunity"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e0206205","DOI":"10.1371\/journal.pone.0206205","article-title":"The economic burden of CIDP in the United States: a case-control study","volume":"13","author":"Divino","year":"2018","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"201657","DOI":"10.1155\/2014\/201657","article-title":"Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations","volume":"2014","author":"Ripellino","year":"2014","journal-title":"Autoimmune Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1007\/s00415-018-8948-y","article-title":"Corticosteroids in chronic inflammatory demyelinating polyneuropathy: a retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone","volume":"265","author":"van Lieverloo","year":"2018","journal-title":"J Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/mus.24109","article-title":"Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy","volume":"50","author":"Guptill","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1007\/s00415-020-09998-8","article-title":"Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"268","author":"Querol","year":"2021","journal-title":"J Neurol"},{"key":"ref21","first-page":"S380","article-title":"The economic burden and managed care implications of chronic inflammatory demyelinating polyneuropathy","volume":"24","author":"Owens","year":"2018","journal-title":"Am J Manag Care"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"108017","DOI":"10.1016\/j.clineuro.2023.108017","article-title":"Impact of social-functioning and sleep on quality of life in chronic inflammatory demyelinating polyneuropathy","volume":"234","author":"Englezou","year":"2023","journal-title":"Clin Neurol Neurosurg"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s40120-023-00478-5","article-title":"Intravenous immunoglobulin treatment patterns and outcomes in patients with chronic inflammatory demyelinating Polyradiculoneuropathy: a US claims database analysis","volume":"12","author":"Anderson-Smits","year":"2023","journal-title":"Neurol Ther"},{"key":"ref24","volume-title":"Komodo Health: comprehensive patient journey data","year":"2024"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1007\/s00415-020-09916-y","article-title":"Impact of environmental factors and physical activity on disability and quality of life in CIDP","volume":"267","author":"Doneddu","year":"2020","journal-title":"J Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1111\/ene.14796","article-title":"Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"28","author":"Broers","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/archneur.62.2.249","article-title":"Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone","volume":"62","author":"Lopate","year":"2005","journal-title":"Arch Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/mus.27356","article-title":"Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy","volume":"64","author":"Goyal","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40264-023-01326-z","article-title":"Safety and tolerability of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: results of the ProCID study","volume":"46","author":"Cornblath","year":"2023","journal-title":"Drug Saf"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/archneurol.2010.105","article-title":"Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"67","author":"Latov","year":"2010","journal-title":"Arch Neurol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1726857\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:26:32Z","timestamp":1771925192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1726857\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":31,"alternative-id":["10.3389\/fneur.2025.1726857"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1726857","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"article-number":"1726857"}}